TragediesSafetydatabasesSulfanilamideOuraRingFDAPrivacypolicyFairnessRadioactivehazardEfficacyDemographicsAntifreezeHumanoversightBlackboxmodelsNaturallanguageprocessingBiasPharmacovigilanceDisproportionalityanalysisOpioidcrisisAccidentaldiscoveryClinicaltrialsPatientforumsDecisionfatigueDataheterogeneityWearabletechRealworlddataDataprivacyOxycontinDrug-inducedliver injuryDrugregulationPharmaceuticalsPalantirGeorgeWashingtonHIPAAInnovationFinancialburdenPublictrustResponsibilityPhase1InterpretabilityAskFDALabelEvidencebasedTransparencyIBMWatsonTraditionDuplicatedetectionBalancedpartnershipBreakthroughsPenicillinAIintegrationEMAPharmBERTEfficiencySafetySignaldetectionLongtermsafetyToxiccompoundOverdoseLifecyclegovernanceThalidomideRaresideeffectsIdentitytheftAddictionBloodlettingFutureimplicationsConfidentialityPatientsafetyPatientrecruitmentRadithorGlobalharmonisationHumorsUnsaferecommendationsCybersecurityCaseprocessingTrustMedicalcodingRisk-basedapproachInnovationvs cautionCIOMSTragediesSafetydatabasesSulfanilamideOuraRingFDAPrivacypolicyFairnessRadioactivehazardEfficacyDemographicsAntifreezeHumanoversightBlackboxmodelsNaturallanguageprocessingBiasPharmacovigilanceDisproportionalityanalysisOpioidcrisisAccidentaldiscoveryClinicaltrialsPatientforumsDecisionfatigueDataheterogeneityWearabletechRealworlddataDataprivacyOxycontinDrug-inducedliver injuryDrugregulationPharmaceuticalsPalantirGeorgeWashingtonHIPAAInnovationFinancialburdenPublictrustResponsibilityPhase1InterpretabilityAskFDALabelEvidencebasedTransparencyIBMWatsonTraditionDuplicatedetectionBalancedpartnershipBreakthroughsPenicillinAIintegrationEMAPharmBERTEfficiencySafetySignaldetectionLongtermsafetyToxiccompoundOverdoseLifecyclegovernanceThalidomideRaresideeffectsIdentitytheftAddictionBloodlettingFutureimplicationsConfidentialityPatientsafetyPatientrecruitmentRadithorGlobalharmonisationHumorsUnsaferecommendationsCybersecurityCaseprocessingTrustMedicalcodingRisk-basedapproachInnovationvs cautionCIOMS

BIEN4110 - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
  1. Tragedies
  2. Safety databases
  3. Sulfanilamide
  4. Oura Ring
  5. FDA
  6. Privacy policy
  7. Fairness
  8. Radioactive hazard
  9. Efficacy
  10. Demographics
  11. Antifreeze
  12. Human oversight
  13. Black box models
  14. Natural language processing
  15. Bias
  16. Pharmacovigilance
  17. Disproportionality analysis
  18. Opioid crisis
  19. Accidental discovery
  20. Clinical trials
  21. Patient forums
  22. Decision fatigue
  23. Data heterogeneity
  24. Wearable tech
  25. Realworld data
  26. Data privacy
  27. Oxycontin
  28. Drug-induced liver injury
  29. Drug regulation
  30. Pharmaceuticals
  31. Palantir
  32. George Washington
  33. HIPAA
  34. Innovation
  35. Financial burden
  36. Public trust
  37. Responsibility
  38. Phase 1
  39. Interpretability
  40. AskFDALabel
  41. Evidencebased
  42. Transparency
  43. IBM Watson
  44. Tradition
  45. Duplicate detection
  46. Balanced partnership
  47. Breakthroughs
  48. Penicillin
  49. AI integration
  50. EMA
  51. PharmBERT
  52. Efficiency
  53. Safety
  54. Signal detection
  55. Longterm safety
  56. Toxic compound
  57. Overdose
  58. Lifecycle governance
  59. Thalidomide
  60. Rare side effects
  61. Identity theft
  62. Addiction
  63. Bloodletting
  64. Future implications
  65. Confidentiality
  66. Patient safety
  67. Patient recruitment
  68. Radithor
  69. Global harmonisation
  70. Humors
  71. Unsafe recommendations
  72. Cybersecurity
  73. Case processing
  74. Trust
  75. Medical coding
  76. Risk-based approach
  77. Innovation vs caution
  78. CIOMS